Medical Voice 28th August 2020 |
Clinical News
eMediNexus Coverage from: 
Medical Voice 28th August 2020

0 Read Comments                

Covid-19 tests will now be required for nursing home staff

WASHINGTON: Scrambling to check the spread of COVID-19 in nursing homes, the Trump administration announced Tuesday it will require facilities to test staff regularly or face fines. The move comes months after the White House first urged governors to test all nursing home residents and staff. With residents, nursing homes are being required to offer them coronavirus tests if there is an outbreak or if any show symptoms. Long-term care facilities represent less than 1% of the U.S. population, but they account for 42% of the COVID-19 deaths, with more than 70,000 fatalities reported by the COVID Tracking Project. ....read more

Hospital Issues in Covid-19 Era

Are you aware of holistic and integrated care?Join us today as we explore some of the hospital-related issues which are of paramount importance in the COVID-19 era on Medtalks with Dr K K Aggarwal COVID edition at 7:00 pm. Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php 

CMAAO Coronavirus Facts and Myth Buster: COVID-19 and Dentistry

With input from Dr Monica Vasudev 1067: IMA-CMAAO Webinar on “COVID-19 and Dentistry” Participants: Dr KK Aggarwal, President CMAAO, Dr Ramesh K Datta, Hony Finance Secretary IMA, Dr Jayakrishnan Alapet, Dr S Sharma Faculty: Prof (Dr) Mahesh Verma, Prosthodontist, Vice Chancellor, Guru Gobind Singh Indraprastha University, Former Director and Principal of Maulana Azad Institute of Dental Sciences Key points from the discussion:Dentistry has progressed in the past few decades and it is now a huge group of Dental Sciences. Nine specialties where MDS is offered: Oral Medicine & Radiology, Prosthodontics, Conservative Dentistry & Endodontics, Orthodontics, Pediatric Dentistry and Preventive Dentistry, Periodontology, Oral & Maxillofacial Surgery, Oral Pathology and Public Health Dentistry. ....read more

World COVID Meter 26th August: Acute manageable immuno-thrombo-inflammatory viral disease with post viral phase, 213 Countries Affected

Cases: 1M April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June 29th, 11M July 4, 12M July 8, 13M July 13, 14M July 17, 15M July 23, 16M July 25, 17M July 29, 18M August 1, 19M August 6, 20M August 10, 21M August 16, 22M August 19, 23M August 21 Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity Coronavirus Cases: 24,048,856,Deaths: 823,180,Recovered: 16,597,318,ACTIVE CASES 6,628,358,Currently Infected Patients 6,566,565 (99%) in Mild Condition ....read more

The very purpose of life is to face sufferings

According to Hinduism, the very fact we are born means that in our last life, we did not get liberation or Moksha. It also means that some sufferings in our last birth still remained. Therefore, the purpose of this birth is to face those sufferings. When the purpose of our life is to face sufferings, why suffer from them? This should be considered as ‘sukh’ and not ‘dukh’. As per Vedic literature, every adversity is an opportunity to learn or to do something different. The notable principles of Buddhism also talk about the same. The first is that suffering exists, second that there is a reason for every suffering and third that it is possible to neutralize the suffering by understanding the 8 paths of cessation of suffering. Also remember that in every ‘dukh’ you think of ‘sukh’ and in every ‘sukh’ you think of a ‘dukh’. Next time you have a problem, think differently and learn to enjoy them. ....read more

Healthcare News Monitor

Intas gets DCGI nod for clinical trials of hyperimmune globulin for COVID-19 treatment

Intas Pharma has received permission from the Drug Controller General of India (DCGI), to conduct clinical trial of its COVID-19 specific hyperimmune globulin as treatment for patients suffering from moderate to severe COVID-19 infection. ”Hyperimmune globulin has potential for use as prophylaxis for all high-risk population in contact with COVID-19 patients. This could be an important therapeutic option that can potentially help combat the disease until a vaccine is available. Intas is among the world’s first to adopt this approach for treating COVID-19 patients. This will be a Corporate Social Responsibility (CSR) initiative from Intas in collaboration with all Indian blood banks, that will help to procure convalescent plasma (plasma extracted from patients recovered from COVID-19 infection),” informed the company through a statement. Dr Suma Ray, VP & Head of Plasma Operations at Intas, stated, “Hyperimmune globulin will provide purified and enriched preparation of COVID-19 specific neutralising antibodies in high concentration, free from blood transmitted viruses and other plasma proteins. Hyperimmune globulin will also enable consistent, precise dosing and predictable response early in the treatment of COVID-19 infections. Being a specific antibody treatment manufactured specially, it does not require blood group matching or donor selection while administering to the patient besides having huge benefits in terms of assured antibody administration. Unlike plasma therapy, Hyperimmune globulin can be readily administered to the patients anywhere even in the remotest part of the country.”

Lupus, arthritis patients not higher-risk for severe Covid-19: studies

ET Health world

Washington: Most adults with lupus or inflammatory arthritis are not at greater risk of hospitalization from Covid-19, a pair of studies said Tuesday, in what researchers said was reassuring news. Both lupus and more common forms of arthritis cause peoples immune systems to mistakenly attack their own tissues, leading to inflammation in the joints, skin, kidney, and other parts of the body.

Tripura says Tocilizumab, Remdisivir helping in treatment of COVID-19 patients; orders more

The Indian Express

Amid rising COVID-19 figures and a possible outbreak of the virus in the community in coming weeks, the Tripura government Tuesday said it has received good results from using investigational drugs like Tocilizumab and Remdisivir on critical corona patients and has ordered more vials of the drugs. Speaking to reporters, state Law Minister Ratan Lal Nath said the health department has seen ‘positive results’ after using Tocilizumab on COVID-19 patients and their health condition showed a ‘significant improvement’. “We had ordered six vials of Tocilizumab for using on critical patients. The results of these trials were positive and the health department has now decided to place orders for 50 more vials of the drug,” he told reporters. The medicine costs Rs 30,000 a vial, the minister said.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now